Clinical Study

Alliance A031704- Pd-Inhibitor (Nivolumab) And Ipilimumab Followed By Nivolumab Vs. Vegf Tki Cabozantinib With Nivolumab: A Phase III Trial In Metastatic Untreated Renal Cell Cancer [Pdigree]

Posted Date: May 22, 2020

  • Investigator: Robert Franklin
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The goal of the study is to compare the overall survival (OS) in patients with metastatic RCC treated with ipilimumab- nivolumab followed by either nivolumab versus cabozantinib-nivolumab


To Be Eligible: Must Have Renal Cell Carcinoma, Measurable Disease, Karnofsky Performance Status <70%, No Prior Systemic Therapy For Renal Cell Cancer, No Severe Hypersensitivity To Study Drugs, No Active Infection Or Disease That Could Impact Study Treatment


Kidney Cancer, Renal Cell

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.